Domain Therapeutics to present new data on its EP4R and CCR8 antagonists
at 2022 SITC Annual Meeting
- Domain will present two posters on its medical candidate EP4R antagonist, DT-9081,
and one poster on its CCR8 depleting-antibody program
Strasbourg, France – Montreal, Canada, October 6, 2022 – Domain Therapeutics (“Domain” or “the Company”), a drug discovery and growth firm targeted on G Protein-Coupled Receptors (GPCRs) in immuno-oncology, will present data on its proprietary GPCR packages on the Society for Immunotherapy of Cancer (STIC) Annual Meeting, happening on 8-12 November 2022 in Boston, US.
Domain will present two posters on its oral small molecule EP4R antagonist, DT-9081. The first poster will spotlight preclinical data illustrating the synergy of DT-9081 together with immune checkpoint inhibitors in numerous most cancers fashions. The second poster will focus on the medical trial design for the upcoming Phase I medical examine, which is anticipated to begin earlier than the tip of the 12 months.
Domain may also present a poster on its CCR8 depleting-antibody program illustrating key differentiating properties of its patent-protected proprietary sequence of antibodies concentrating on CCR8. It’s identified that this GPCR is particularly expressed on tumor-infiltrating regulatory T cells, a extremely immuno-suppressive cell inhabitants driving tumor development. This goal is at the moment attracting important curiosity for the event of novel game-changing immunotherapies.
Dr. Stephan Schann, VP Research at Domain Therapeutics, commented: “The data to be presented will highlight the potential of our proprietary GPCR programs as attractive immuno-oncology drug candidates. We look forward to presenting these exciting new findings which will demonstrate the potential advantages of our drug candidates, whilst positioning Domain Therapeutics as key player in the field of immunotherapies.”
Details of the poster shows are as follows:
Title: DT-9081, a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce full responses in syngeneic murine most cancers fashions
Abstract quantity: #814
Location: Omni Boston Hotel, 450 Summer Street, Boston, MA 02210, Poster Hall, Hall C
Date and time: 11/10/2022 – 11/11/2022 9:00am – 9:00pm
Title: First in human part I trial of DT-9081, a selective EP4 receptor antagonist in patients with recurrent and/or metastatic stable tumors
Abstract quantity: #741
Location: Omni Boston Hotel, 450 Summer Street, Boston, MA 02210, Poster Hall, Hall C
Date and time: 11/10/2022 – 11/11/2022 9:00am – 9:00pm
Title: Beyond CCR8: key epitopes concentrating on dynamic CCR8 conformational states and a variety of monoclonal antibodies to modulate the tumor microenvironment for the therapy of cancers
Abstract quantity: #1393
Location: Omni Boston Hotel, 450 Summer Street, Boston, MA 02210, Poster Hall, Hall C
Date and time: 11/10/2022 – 11/11/2022 9:00am – 9:00pm
– ENDS –
For extra info, please contact:
Consilium Strategic Communications
Amber Fennell, Angela Gray, Namrata Taak
Email: [email protected]
Tel: +44 (0)20 3709 5813
NewCap (for French media)
Annie-Florence Loyer
Email: [email protected]
Tel: +33 (0)1.44.71.02.12
About Domain Therapeutics
Domain Therapeutics, a biopharmaceutical firm working in France and Canada, focuses on the invention and growth of new drug candidates concentrating on G Protein-Coupled Receptors (GPCRs), some of the vital drug goal courses. The Company develops high-value drug candidates to handle GPCR-mediated immunosuppression in immuno-oncology and raised €39m in early 2022.
www.domaintherapeutics.com
